Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15632175 | 1.00 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3UCHL1 | |
| SCHEMBL8262943 | 1.00 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3UCHL1 | |
| SCHEMBL15632464 | 1.00 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3UCHL1 | |
| SCHEMBL14371725 | 1.00 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3UCHL1 | |
| SCHEMBL30680515 | 1.00 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3UCHL1 | |
| SCHEMBL16857486 | 1.00 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3UCHL1 | |
| SCHEMBL24739167 | 0.88 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL14371726 | 0.84 | UCHL1 (0.37) | NR1H2CHRM2CHRM1CHRM3UCHL1 | |
| SCHEMBL7707939 | 0.83 | CHRM2 (0.39) | NR1H2CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL7712028 | 0.83 | CHRM2 (0.39) | NR1H2CHRM2CHRM1CHRM3HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4640279-A2 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2025-10-29 | — | — | EP | disclosed |
| EP-4356969-B1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2025-07-09 | — | — | EP | disclosed |
| US-20250011334-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2025-01-09 | — | — | US | disclosed |
| CN-113683614-B | Fused tricyclic pyridazinone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-4356969-A2 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-11912715-B2 | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| EP-3848372-B1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011334-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | ZC3HAV1, ZC3HAV1L, CUL1 | NR1H2 839/4885CHRM2 1617/4885CHRM1 621/4885 |
| US-11912715-B2 | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections | ZC3HAV1, ZC3HAV1L, CUL5 | NR1H2 816/4885CHRM2 1650/4885CHRM1 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.